Top Markets
#1 QuantixAI QuantixAI +102.23%
#2 Pons Pons +31.77%
#3 龙虾 (Lobster) 龙虾 (Lobster) +31.60%
#4 Rain Rain +30.90%
#5 MetaDAO MetaDAO +27.67%
#6 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +24.74%
#7 Bedrock Bedrock +20.57%
#8 Ontology Gas Ontology Gas +18.03%
#9 Prom Prom +18.01%
#10 peaq peaq +16.66%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
Sinew Pharma Inc. Sinew Pharma Inc.

Sinew Pharma Inc.

6634
Rank in Stocks #20256
Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research,... Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of new therapeutics. Its core mission revolves around pioneering innovative solutions for hepatotoxicity-free acetaminophen and addressing various fatty liver conditions. The company's robust pipeline features SNP-610, a drug candidate currently advancing through Phase II clinical trials in Taiwan for the treatment of non-alcoholic steatohepatitis (NASH). Another early-stage compound, SNP-630, is also in preclinical development, targeting NASH. Beyond liver disease, Sinew Pharma is progressing SNP-810 for its analgesic and antipyretic properties. Furthermore, the firm is developing SNP-830 and SNP-840, positioned as liver-safe pain medications specifically for the United States market. Established in 2014, Sinew Pharma Inc. maintains its headquarters in Taipei City, Taiwan.
Share Price
$1.90
Market Cap
$135.79M
Change (1 day)
-0.50%
Change (1 year)
20.89%
Country
TW
Trade Sinew Pharma Inc. (6634)

Category

Healthcare
Revenue for Sinew Pharma Inc. (6634)
Revenue in Aug 2026 TTM: 0
According to Sinew Pharma Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sinew Pharma Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH